Abstract
Background
In hypoxic conditions, miRNA-210 plays an important role in regulating the expression of hypoxia-inducing factor-1α (HIF-1α) and the differentiation of T helper 17 (Th17) cells, and this may be involved in the development and function of the immune system.
Aims
This study was to investigate the miR-210 expression levels in peripheral blood mononuclear cells (PBMCs) from patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) and its association with the clinical and laboratory features of both diseases.
Methods
Real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR) was used to detect miR-210 expression levels in PBMCs from 35 patients with SLE, 38 patients with RA, and 35 healthy controls.
Results
Compared with the healthy controls, the miR-210 expression levels were significantly increased in patients with SLE (P = 0.001) and there was increased significantly expression of miR-210 in SLE with pleuritis (Z = −2.345, P = 0.019) and anti-SSB/La-positive group (Z = −2.076, P = 0.038). However, we have not found the significant correlation between the miR-210 levels and the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score (r s = 0.091, P = 0.602). Although, no significant difference between miR-210 levels in RA patients and those in healthy controls was found (Z = −1.226, P = 0. 220). There was a significant decreased expression of miR-210 in active RA patients than inactive RA patients (Z = −4.011, P < 0.001).
Conclusions
The dysregulation of miR-210 levels in SLE and RA patients suggests that miR-210 might play an important role in the pathogenesis of these diseases.
Similar content being viewed by others
References
Perera RJ, Ray A (2007) MicroRNAs in the search for understanding human diseases. BioDrugs 21(2):97–104. doi:10.2165/00063030-200721020-00004
Ambros V (2003) MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell 113(6):673–676
Ambros V (2004) The functions of animal microRNAs. Nature 431(7006):350–355. doi:10.1038/nature02871
Leung AK, Sharp PA (2010) MicroRNA functions in stress responses. Mol Cell 40(2):205–215. doi:10.1016/j.molcel.2010.09.027
Chan YC, Banerjee J, Choi SY et al (2012) miR-210: the master hypoxamir. Microcirculation 19(3):215–223. doi:10.1111/j.1549-8719.2011.00154.x
Camps C, Buffa FM, Colella S et al (2008) hsa-miR-210 is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res 14(5):1340–1348. doi:10.1158/1078-0432.CCR-07-1755
Giannakakis A, Sandaltzopoulos R, Greshock J et al (2008) miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther 7(2):255–264
Huang X, Le QT, Giaccia AJ (2010) MiR-210--micromanager of the hypoxia pathway. Trends Mol Med 16(5):230–237. doi:10.1016/j.molmed.2010.03.004
Wang H, Flach H, Onizawa M et al (2014) Negative regulation of Hif1a expression and TH17 differentiation by the hypoxia-regulated microRNA miR-210. Nat Immunol 15(4):393–401. doi:10.1038/ni.2846
Rahman A, Isenberg DA (2008) Systemic lupus erythematosus. N Engl J Med 358(9):929–939. doi:10.1056/NEJMra071297
Wong JB, Ramey DR, Singh G (2001) Long-term morbidity, mortality, and economics of rheumatoid arthritis. Arthritis Rheum 44(12):2746–2749
Lajas C, Abasolo L, Bellajdel B et al (2003) Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Athritis Rheum 49(1):64–70. doi:10.1002/art.10905
Alunno A, Bartoloni E, Bistoni O et al (2012) Balance between regulatory T and Th17 cells in systemic lupus erythematosus: the old and the new. Clin Dev Immunol 2012:823085. doi:10.1155/2012/823085
Annunziato F, Cosmi L, Liotta F et al (2009) Type 17 T helper cells-origins, features and possible roles in rheumatic disease. Nat Rev Rheumatol 5(6):325–331. doi:10.1038/nrrheum.2009.80
Eltzschig HK, Carmeliet P (2011) Hypoxia and inflammation. N Engl J Med 364(7):656–665. doi:10.1056/NEJMra0910283
Dang EV, Barbi J, Yang HY et al (2011) Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell 146(5):772–784. doi:10.1016/j.cell.2011.07.033
Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725. doi:10.1002/1529-0131(199709)40:9<1725::AID-ART29>3.0.CO;2-Y
Silman AJ (1988) The 1987 revised American Rheumatism Association criteria for rheumatoid arthritis. Br J Rheumatol 27(5):341–343
Gladman DD, Ibañez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index. 2000. J Rheumatol 29(2):288–291
Eis PS, TamW SL et al (2005) Accumulation of miR- 155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A 102(10):3627–3632. doi:10.1073/pnas.0500613102
Fulci V, Chiaretti S, Goldoni M et al (2007) Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood 109(11):4944–4951. doi:10.1182/blood-2006-12-062398
Turunen S, Koivula MK, Melkko J et al (2013) Different amounts of protein-bound citrulline and homocitrulline in foot joint tissues of a patient with anti-citrullinated protein antibody positive erosive rheumatoid arthritis. J Transl Med 11:224. doi:10.1186/1479-5876-11-224
Rodriguez A, Vigorito E, Clare S et al (2007) Requirement of bic/microRNA- 155 for normal immune function. Science 316(5824):608–611. doi:10.1126/science.1139253
Labbaye C, Spinello I, Quaranta MT et al (2008) A three-step pathway comprising PLZF/miR146a/CXCR4 controls megakaryopoiesis. Nat Cell Biol 10(7):788–801. doi:10.1038/ncb1741
Zhou M, Li LH, Peng H et al (2014) Decreased ITGAM and FcgammaRIIIA mRNA expression levels in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Exp Med 14(3):269–274. doi:10.1007/s10238-013-0240-y
Wong CK, Lit LC, Tam LS et al (2008) Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol 127(3):385–393. doi:10.1016/j.clim.2008.01.019
Zhao XF, Pan HF, Yuan H et al (2010) Increased serum interleukin 17 in patients with systemic lupus erythematosus. Mol Biol Rep 37(1):81–85. doi:10.1007/s11033-009-9533-3
Semenza GL (2007) Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE 2007(407):cm8. doi:10.1126/stke.4072007cm8
Taganov KD, Boldin MP, Baltimore D MicroRNAs and immunity: tiny players in a big field. Immunity 26(2):133–137. doi:10.1016/j.immuni.2007.02.005
Xiao C, Rajewsky K (2009) MicroRNA control in the immune system: basic principles. Cell 136(1):26–36. doi:10.1016/j.cell.2008.12.027
O’Neill LA, Sheedy FJ, McCoy CE (2011) MicroRNAs: the fine-tuners of Toll-like receptor signalling. Nat Rev Immunol 11(3):163–175. doi:10.1038/nri2957
Qi J, Qiao Y, Wang P et al (2012) microRNA-210 negatively regulates LPS-induced production of proinflammatory cytokines by targeting NF-kappaB1 in murine macrophages. FEBS Lett 586(8):1201–1207. doi:10.1016/j.febslet.2012.03.011
Zhang D, Cao X, Li J et al (2015) MiR-210 inhibits NF-kappaB signaling pathway by targeting DR6 in osteoarthritis. Sci Rep 5:12775. doi:10.1038/srep12775
Qiu J, Zhou XY, Zhou XG et al (2013) Neuroprotective effects of microRNA-210 on hypoxic-ischemic encephalopathy. Biomed Res Int 2013:350419. doi:10.1155/2013/350419
Zhao L, Nocturne G, Haskett S et al (2017) Clinical relevance of RORγ positive and negative subsets of CD161+CD4+ T cells in primary Sjögren’s syndrome. Rheumatology (Oxford) 56(2):303–312. doi:10.1093/rheumatology/kew360
Osipova J, Fischer DC, Dangwal S et al (2014) Diabetes-associated microRNAs in pediatric patients with type 1 diabetes mellitus: a cross-sectional cohort study. J Clin Endocrinol Metab 99(9):E1661–E1665. doi:10.1210/jc.2013-3868
Yang D, Wang WZ, Zhang XM et al (2014) MicroRNA expression aberration in Chinese patients with relapsing remitting multiple sclerosis. J Mol Neurosci 52(1):131–137. doi:10.1007/s12031-013-0138-x
Acknowledgements
Thank you to the First Affiliated Hospital of Anhui Medical University and Anhui Provincial Hospital.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This study was supported by the National Natural Science Foundation of China (81172764).
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Novelty statement
The expression of miR-210 was detected by RT-qPCR in these patients. This research is the first study to investigate the miR-210 expression levels in peripheral blood mononuclear cells (PBMCs) from patients with SLE and RA. And the results can provide an evidence for the further study of its function in the pathogenesis of SLE and RA.
Rights and permissions
About this article
Cite this article
Huang, Q., Chen, SS., Li, J. et al. miR-210 expression in PBMCs from patients with systemic lupus erythematosus and rheumatoid arthritis. Ir J Med Sci 187, 243–249 (2018). https://doi.org/10.1007/s11845-017-1634-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11845-017-1634-8